Benzinga | Aug 6, 2020 11:26AM EDT

BMO Capital Maintains Outperform on Horizon Therapeutics, Raises Price Target to $105

BMO Capital maintains Horizon Therapeutics (NASDAQ:HZNP) with a Outperform and raises the price target from $70 to $105.